Black Diamond Therapeutics’ (BDTX) Buy Rating Reiterated at HC Wainwright

HC Wainwright restated their buy rating on shares of Black Diamond Therapeutics (NASDAQ:BDTX) in a research report released on Wednesday, Benzinga reports. The brokerage currently has a $11.00 price objective on the stock.

A number of other equities analysts have also weighed in on BDTX. Piper Sandler restated an overweight rating and issued a $12.00 target price on shares of Black Diamond Therapeutics in a research note on Wednesday, July 3rd. Wedbush restated an outperform rating and issued a $16.00 price objective on shares of Black Diamond Therapeutics in a research report on Tuesday, September 10th. Finally, Raymond James assumed coverage on shares of Black Diamond Therapeutics in a research report on Wednesday, July 31st. They set an outperform rating and a $20.00 target price for the company.

Black Diamond Therapeutics Stock Down 2.0 %

Shares of BDTX opened at $4.73 on Wednesday. Black Diamond Therapeutics has a twelve month low of $1.62 and a twelve month high of $7.66. The stock has a market cap of $266.08 million, a PE ratio of -2.85 and a beta of 2.49. The business’s 50-day moving average price is $5.72 and its 200-day moving average price is $5.35.

Black Diamond Therapeutics (NASDAQ:BDTX) last posted its earnings results on Tuesday, August 6th. The company reported ($0.36) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.39) by $0.03. Analysts expect that Black Diamond Therapeutics will post -1.4 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Black Diamond Therapeutics

A number of hedge funds and other institutional investors have recently modified their holdings of BDTX. Susquehanna Fundamental Investments LLC purchased a new position in shares of Black Diamond Therapeutics during the 1st quarter valued at about $82,000. Foundations Investment Advisors LLC raised its stake in shares of Black Diamond Therapeutics by 17.7% during the second quarter. Foundations Investment Advisors LLC now owns 113,550 shares of the company’s stock worth $529,000 after acquiring an additional 17,050 shares in the last quarter. Acadian Asset Management LLC lifted its holdings in shares of Black Diamond Therapeutics by 13.8% in the 1st quarter. Acadian Asset Management LLC now owns 170,510 shares of the company’s stock worth $864,000 after acquiring an additional 20,616 shares during the last quarter. SG Americas Securities LLC purchased a new stake in shares of Black Diamond Therapeutics in the 2nd quarter valued at $108,000. Finally, Jump Financial LLC grew its holdings in shares of Black Diamond Therapeutics by 245.0% during the 4th quarter. Jump Financial LLC now owns 38,888 shares of the company’s stock valued at $109,000 after purchasing an additional 27,616 shares during the last quarter. 95.47% of the stock is currently owned by hedge funds and other institutional investors.

Black Diamond Therapeutics Company Profile

Black Diamond Therapeutics, Inc, a clinical-stage oncology medicine company, focuses on the discovery and development of MasterKey therapies for patients with genetically defined tumors. The company's lead product candidate is BDTX-1535, a brain-penetrant epidermal growth factor receptor MasterKey inhibitor, which is in phase 2 clinical trial for the treatment of epidermal growth factor receptor mutant non-small cell lung cancer, as well as phase 1 clinical trial to treat glioblastoma.